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The purpose of the present study was to describe the prevalence, incidence and geographic
variation of glaucoma in Denmark in the period from 1996 to 2011. Moreover, the aim was
to identify the treatment patterns of glaucoma within the studied period.
Methods
All Danish citizens were included throughout the study period. The National Prescription
Registry was used to identify all claimed prescriptions for glaucoma medication.
Results
A total of 116,592 incident glaucoma patients were identified. Average age at onset was 66
years (range: 0–105 years), 55% were women. The prevalence of glaucoma increased
from 0.79% to 1.72% during the investigated period. In 2011 glaucoma affected 3.76% of
the population above 50 years and 10% in patients above 80 years. The age-specific inci-
dence rate of glaucoma seemed to be constant and the increasing prevalence was primarily
attributed to an aging population. We found the highest prevalence of glaucoma in the capi-
tal region of Denmark. Within the studied period the use of prostaglandin analogs and com-
bination drugs increased, whereas the use of β-blockers, carbon anhydrase inhibitors and
parasympathomimetic drugs decreased (p<0.001). Finally, the use of α2-adrenergic ago-
nists remained unchanged. A total of 75% of the patients were treated with two or more
glaucoma medications.
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Conclusions
Over all, the present study is the first to assess the frequency and the development of glau-
coma in Denmark over a 15-year period. We find that glaucoma affects a little less than 2%
of the total population and increases with age to reach a prevalence of more than 10%
amongst people above 80 years. Generally, the present study is the largest nation-wide
study ever made and must be a close-to-real-life-picture of the utilization of glaucoma medi-
cation on a national scale. Our findings confirm other recent estimations on an increasing
burden of glaucoma globally.
Introduction
Glaucoma is one of the leading causes of blindness worldwide. According to TheWorld Health
Organization glaucoma accounted for 2% of visual impairment and 8% of global blindness in 2010,
and the number of glaucoma patients is estimated to increase due to an aging population[1–3].
Generally, glaucoma refers to a group of eye conditions, which cause progressive damage to the
optic nerve. If untreated, glaucoma will lead to permanent vision loss starting with unnoticeable
blind spots at the edges of the field of vision, progressing to tunnel vision, and in worst case lead to
blindness. The classification of glaucoma relies on the appearance and obstruction of the drainage
pathway. In open angle glaucoma (OAG) the drainage pathway appears normal and in angle-clo-
sure glaucoma (ACG) the drainage pathway is obstructed. The pathogenesis of glaucoma is multi-
factorial. However, the intra ocular pressure (IOP) is the most evident risk factor for glaucomatous
damage and to date IOP lowering drugs remain the only clinically validated treatment of glaucoma
[4,5]. Historically, the first person to link IOP to the glaucoma was the English ophthalmologist,
Richard Bannister, who described the phenomenon in 1622[6]. In1862 it was recognized that the
extract from the calabar bean could counteract mydriasis, and in 1876 pilocarpin was introduced.
The development of pressure lowering drugs accelerated in 1978 with the approval of Timolol[6].
In addition to glaucomamedication, glaucoma surgery has been performed since 1856 when
Albrecht von Graefe introduced iridectomy. Hundred years later the most common glaucoma sur-
gical procedure, trabeculectomy, was developed[7,8]. In spite of the development of more surgical
procedures the far most predominant treatment of glaucoma is pressure lowering eye drops.
The prevalence of glaucoma has been reported in numerous studies and significant ethnic
and geographic differences have been found. In spite of the unique possibility to estimate the
prevalence of glaucoma in the entire population in Denmark only a few epidemiologic studies
have been performed. To our knowledge the first study to estimate the number of glaucoma
patients in Denmark was performed in 1989. This study was based on a national consumption
of anti-glaucomatous drugs and revealed a prevalence of 0.76% in the age group above 40 years
[9]. A follow up of this study was performed in 2000 based on a questionnaire survey among
private practice ophthalmologists in Denmark. In this study the prevalence in Denmark was
estimated to 0.65% in the entire population[10]. A recent study focused on the annual costs of
glaucoma in Denmark and revealed an incidence rate of 1.2 per 1000 adults in the period from
2002 to 2007[11]. To our knowledge no previous study has benefited from a complete data
sample from an entire population to estimate the incidence and prevalence of glaucoma.
Hence, the purpose of the study was to describe the incidence and prevalence of glaucoma
in the Danish population throughout a fifteen-year period. Furthermore, we wanted to investi-
gate the geographic variation of glaucoma in Denmark and characterize the utilization pattern
of glaucoma medication in the aforementioned period.
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Methods
Population
The study population comprised all individuals living in Denmark in the period from 1996 to
2011. The government financed healthcare system requests all pharmacies in Denmark to reg-
ister all prescriptions at an individual level by the so-called CPR-number. Likewise, the Danish
National Registry of Patients has collected discharge diagnoses from public and private hospi-
tals in Denmark since 1977. From 1995 the registry has used diagnoses as coded in the ICD-10.
Information on glaucoma medication was obtained from the Danish Registry of Medicinal
Product Statistics. Following prescriptions were regarded as glaucoma medication (ATC-
codes: S01ED01-05 = β-blockers; S01EE = prostaglandin analogs; S01EA = α2-adrenergic ago-
nists, S01EB = parasympathomimetic drugs, S01EC = carbon anhydrase inhibitors; S01EA51,
S01EB51, S01ED51 = fixed combination drugs).
Glaucoma was defined as a disorder treated as glaucoma. Patients were classified as “inci-
dent” by the time of their first prescription of glaucoma medication. Patients were categorized
according to their number of treatment changes. A treatment change was defined as the start
of a glaucoma treatment with more than 180-day time-wise gap between two purchases of glau-
coma medicine.
Statistics
Incidence rates were calculated in ten-year age strata. As previously mentioned, patients were
classified as “incident” by the time of their first prescription of glaucoma medication. Incidence
rate was defined as: new glaucoma cases, in each age strata, divided by the size of the Danish
population (age strata). Prevalence was defined as: patients living with glaucoma, i.e., being
treated with glaucoma medication, in each age strata, divided by the size of the Danish popula-
tion, in each age strata.
The statistical analysis made use of the Poisson distribution and Two-proportion z-test.
All statistics were performed in SAS 9.2. P-values below 0.05 (two-sided) were considered
significant. GIS Maps were performed in Arc Map 10.1.
Ethics
The Danish Data Protection Agency approved the study (2007-58-0015, int. ref: GEH-2010-
001). Retrospective register-based studies do not require ethical approval in Denmark.
Results
A total of 116,592 incident glaucoma patients were identified in the period from 1996 to 2011,
and 55% of the patients were females. The average age at onset was 66 (range: 0–105) years.
Mean age for females was 68 years compared to 64 years for males. Baseline characteristics are
shown in Table 1.
The majority of the cases (93.9%) were born in Denmark. The rest of the studied population
was either from other Scandinavian countries (1.0%) or from countries outside of Scandinavia
(5.0%). Data on nationality were missing in 0.1% of the cases.
Incidence
The numeric incidence increased from 7200 to 8600 new glaucoma patients annually
(p< 0.0001) in the period from 1996 to 2011. The increase was attributed to an aging popula-
tion (Fig 1C, Table 1). Thus, the age specific incidence rate of glaucoma did not change during
the study period (Fig 1D).
The Pattern of Glaucoma in Denmark in a 15-Year Period
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Prevalence
A significant increase in the prevalence was seen in the period from 1996 to 2011. In 1996, the
prevalence of glaucoma was 0.79% compared to 1.72% in 2011 (p< 0.0001). The prevalence
was higher in females in the entire period (Table 1 and Table 2). However, the gender differ-
ences diminished during the period under investigation from a female to male ratio of 1.4 in
1996 to 1.2 in 2011 (Table 1). Glaucoma was more common in the elderly and affected approx-
imately 10% of the population in the age group above 80 years, and as much as 15% in the pop-
ulation above 90 years (Fig 1, Table 2).
Geographic differences
The prevalence of glaucoma differed in the five regions of Denmark with a significantly higher
number of cases in the capital region of Denmark. In this region the prevalence was 6.28%
(95CI 6.21–6.36) compared to a prevalence of 3.96% (95CI 3.86–4.06) in the Northern part of
Denmark (Fig 2, Table 3). Interestingly, these differences were unrelated to the geographical
age-distributions (Table 2).
Table 1. Baseline characteristics of 116,592 glaucoma patients in the Danish population in the period from 1996 to 2011. The total Danish popula-
tion, incidence and prevalence are calculated for each year.
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Glaucoma
New cases 7193 6986 7365 7192 6897 6700 6838 6987 6920 6736 7051 7379 7801 7738 8210 8599
































F (%) 55 57 56 56 55 56 55 55 55 55 55 55 55 54 53 54
M (%) 45 43 44 44 45 44 45 45 45 45 45 45 45 46 47 46
Population
F (x 106) 2.66 2.67 2.68 2.69 2.7 2.7 2.71 2.72 2.73 2.73 2.74 2.75 2.76 2.78 2.79 2.8
M (x 106) 2.59 2.6 2.62 2.63 2.63 2.64 2.65 2.66 2.67 2.68 2.69 2.7 2.71 2.73 2.74 2.76
Total (x 106) 5.25 5.28 5.29 5.31 5.33 5.35 5.37 5.38 5.40 5.41 5.43 5.45 5.48 5.51 5.53 5.56
Incidence
F (‰) 1.55 1.51 1.54 1.5 1.41 1.39 1.39 1.42 1.4 1.35 1.42 1.47 1.55 1.49 1.56 1.64
M (‰) 1.19 1.14 1.24 1.2 1.18 1.11 1.16 1.17 1.16 1.13 1.17 1.24 1.3 1.31 1.41 1.45
Total (‰) 1.37 1.32 1.39 1.35 1.29 1.25 1.27 1.3 1.28 1.24 1.3 1.35 1.42 1.4 1.48 1.55
> 50 Y (%) 0.51 0.62 0.4 0.55 0.33 0.49 0.31 0.52 0.36 0.6 0.4 0.61 0.41 0.54 0.35 0.48
F > 50 Y (%) 0.55 0.71 0.34 0.55 0.24 0.42 0.2 0.5 0.28 0.68 0.36 0.7 0.37 0.53 0.25 0.39
M > 50 Y
(%)
0.47 0.55 0.47 0.54 0.46 0.54 0.46 0.54 0.46 0.54 0.46 0.54 0.46 0.55 0.46 0.55
Prevalence
F (%) 0.94 1.02 1.11 1.19 1.26 1.32 1.38 1.44 1.49 1.54 1.60 1.65 1.72 1.77 1.83 1.90
M (%) 0.65 0.72 0.79 0.86 0.92 0.97 1.03 1.08 1.13 1.18 1.23 1.28 1.34 1.40 1.47 1.54
Total (%) 0.79 0.87 0.95 1.03 1.09 1.15 1.2 1.26 1.32 1.36 1.42 1.47 1.53 1.58 1.65 1.72
> 50 Y (%) 2.09 2.23 2.38 2.5 2.62 2.72 2.82 2.92 3.02 3.12 3.22 3.32 3.42 3.51 3.63 3.76
F > 50 Y (%) 2.4 2.56 2.73 2.86 2.99 3.1 3.21 3.32 3.44 3.53 3.63 3.72 3.83 3.92 4.03 4.15
M > 50 Y
(%)
1.73 1.85 1.97 2.08 2.19 2.27 2.37 2.46 2.56 2.66 2.76 2.86 2.96 3.06 3.18 3.32
Abbreviations: F = females; M = males; Y = years.
doi:10.1371/journal.pone.0132048.t001
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Treatment pattern
The “First drug of choice” changed from β-blockers in 1996 to prostaglandin analogs in 2011
(Fig 3, Table 4). In 2011 47% used prostaglandin analogs as mono therapy, whereas only 13%
were treated with β-blockers. Over all, prostaglandin analogs and fixed combination drugs
increased between 1996 and 2011 (p< 0.001), β-blockers, carbonic anhydrase inhibitors and
parasympathomimetic drugs decreased (p< 0.001), whereas the use of α2-adrenergic agonists
were stable (Fig 3, Table 4).
The pattern of combined medication in the period from 1996 to 2011
During the study period 23% of glaucoma patients were treated with two or more glaucoma
medications. The second choice glaucoma medication was often fixed combination drugs.
Patients treated with two separate medications decreased from 20% to 9% throughout the
investigated period (p< 0.001). Moreover, patients treated with more than two glaucoma
drugs decreased from 15% to 0.4% (p< 0.001) (Table 4). Overall, the pattern of glaucoma
treatment revealed a preference of prostaglandin analogs as “first drug of choice” and a switch
to a combination drug as second choice (Table 4).
Fig 1. Prevalence, Incidence and age distribution of glaucoma patients in Denmark. A. Prevalence of glaucoma cases in Denmark in the period from
1996 to 2011. The percentage of female glaucoma patients above 50 years is shown in age intervals of 10 years. A significant increase in the prevalence
throughout the period was found (p < 0.001). No significant difference is seen among females and males (p = 0.8). B. Incidence of glaucoma cases in
Denmark in the period from 1996 to 2011. The percentage of female glaucoma patients above 50 years is shown in age intervals of 10 years. No significant
difference is seen among females and males (p = 0.1). No significant change was observed in the incidence in the studied period. C. The age distribution in
Denmark from 1996 and 2011. In 1996 the total population was 5.3 million and in 2011 5.6 million, respectively. Numbers are drawn from the Danish National
Patient Registry. D. The age specific incidence rates of glaucoma in Denmark in the period from 1996 to 2011. Out of a total of 116,594 cases, the incident
rates reveal a bell shaped distribution with a peak at the age of 80 years by 600 cases per 100,000 person-years.
doi:10.1371/journal.pone.0132048.g001
The Pattern of Glaucoma in Denmark in a 15-Year Period
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Discussion
The present study demonstrated an increasing number of people with glaucoma in the Danish
population in the period from 1996 to 2011. We found a total prevalence of glaucoma of 1.72%
and a prevalence of 3.76% in the population above 50 years. In comparison, previous estima-
tions of the prevalence of glaucoma in Denmark have been significantly lower[9,10].
Until 1996 official medical statistics were published in Denmark. In these reports the whole-
sale of registered pharmaceutical agents were given as “Defined Daily Dosages” per 1000 inhabi-
tants/year. Based on these numbers the total prevalence of glaucoma patients in Denmark was
estimated to 0.33% in 1989[9]. A later study estimated the Danish prevalence of glaucoma based
on questionnaires carried out among Danish Eye Practitioners [10]. Lundberg et al. reported an
overall prevalence on 0.65% well knowing that their study underestimated the true prevalence. A
clear correlation between glaucoma and age was shown. In this matter the prevalence was shown
to increase from 0.5% to 5% in the population at 50 and 80 years, respectively[10].
A recent meta-analysis estimated the prevalence of glaucoma worldwide and revealed a
global prevalence of glaucoma of 3.54% in the population between 40 and 80 years[12]. The
prevalence in Europe was shown to be 2.51[12].
In the present study the estimation of glaucoma cases in Denmark was based on numbers
from the Danish Registry of Medicinal Product Statistics, which allows a more accurate estima-
tion of persons that use glaucoma medication.
Obviously, estimates of a prevalence based on consumption of glaucoma medication are still
associated with considerable inaccuracy. Hence, it is generally accepted that a great number of
glaucoma cases remain undiagnosed. Unrecognized glaucoma subjects are either a result of
ophthalmologists missing the diagnosis or patients not presenting to their ophthalmologist.
Several studies have indicated that around 50% of OAG cases are unrecognized[13–16].
On the other hand over prescription may also bias our results. In this matter it is not
uncommon to find prescriptions for glaucoma drugs in patients with no disc and visual field
Table 2. Demographic prevalence of patients treated with glaucomamedication in 2011. Prevalence rates in 10 years age groups and the gender dis-
tribution are presented.
Capital(M) Capital(F) Zealand(M) Zealand(F) South(M) South (F) Central(M) Central(F) North(M) North (F)
Total pop. 838630 874994 405736 412585 598402 602963 631650 633951 291760 288533
Pop. > 50 Y 0.32 0.35 0.39 0.42 0.37 0.40 0.34 0.37 0.37 0.40
Pop. > 80 Y 0.03 0.05 0.03 0.05 0.03 0.06 0.03 0.05 0.03 0.06
Prevalence
0–9 Y (%) 0.03 0.02 0.00 0.03 0.03 0.01 0.02 0.02 0.02 0.02
10–19 Y (%) 0.10 0.08 0.07 0.04 0.10 0.08 0.09 0.07 0.07 0.03
20–29 Y (%) 0.21 0.23 0.20 0.24 0.23 0.28 0.20 0.26 0.18 0.23
30–39 Y (%) 0.45 0.42 0.53 0.47 0.57 0.46 0.47 0.46 0.48 0.43
40–49 Y (%) 0.73 0.61 0.72 0.56 0.84 0.66 0.76 0.65 0.76 0.65
50–59 Y (%) 1.80 1.78 1.09 1.09 1.48 1.32 1.51 1.60 1.22 1.15
60–69 Y (%) 3.83 4.01 2.43 2.59 2.93 2.93 3.10 3.52 2.28 2.49
70–79 Y (%) 7.27 7.37 5.00 5.06 5.87 6.03 6.09 6.79 4.68 5.12
80–89 Y (%) 12.59 12.97 8.55 9.51 10.28 10.70 9.97 10.83 7.27 8.58
90–99 Y (%) 18.37 18.41 11.78 12.00 14.39 14.38 14.66 13.33 10.78 12.18
100–109 Y (%) 21.05 21.81 7.69 5.94 33.33 15.74 8.33 12.05 12.50 14.71
Abbreviations: Capital = The Capital Region of Denmark; Zealand, Region of Zealand; South = Region of Southern Denmark; Central = Region of Central
Jutland; North = The North Denmark Region; M = Male; F = Female; pop = population; Y = years.
doi:10.1371/journal.pone.0132048.t002
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changes. In addition, treatment with glaucoma medication is often seen in patients with a his-
tory of the highest IOP of less than 25 mmHg. In these scenarios the ophthalmologists
Fig 2. The demographic variation of glaucoma patients in Denmark. The map illustrates the differences in the prevalence of glaucoma cases in the age
group from 50 to 60 years. The highest prevalence of glaucoma is found in the capital region of Denmark with a prevalence of 6.28%, which was significantly
higher compared to the other regions (Table 3). 1) The Capital Region of Denmark, 2) Region of Zealand, 3) Region of Southern Denmark, 4) Region of
Central Jutland, 5) The North Denmark Region.
doi:10.1371/journal.pone.0132048.g002
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overestimate the benefit of therapy, while underestimating the associated risk of treatment[17].
Bearing in mind the aforementioned limitations, we however believe that the cases extracted
from National Prescription Registry lead to a reliable estimate of the prevalence of glaucoma in
Denmark.
Previous studies have shown an increased prevalence of glaucoma in urban areas compared
to rural areas[12]. In the present study the demographic variation of glaucoma cases was esti-
mated in the five existing regions of Denmark. We found a significant higher prevalence of
Fig 3. Total distribution of “first of choice” glaucomamedication in Denmark in the period from 1996 to 2011. The distribution of “first of choice”
medication is shown throughout the study period. The use of β-blockers has decreased (p < 0.001), whereas the use of prostaglandin analogs and
combination drugs has increased in the studied period (p < 0.001). The lower figure shows the time line of the introduction of glaucoma medication (modified
from European Guidelines, 4th edition). Abreviations: β-block., β-blockers; Prostagl., prostaglandin analogs; α-adren., α2-adrenergic agonists; Paras.,
parasympathomimetic drugs; CAI, carbon anhydrase inhibitors; Comb., combination drugs.
doi:10.1371/journal.pone.0132048.g003
Table 3. The demographic variation of glaucoma in Denmark. The incidence and prevalence for 2011 is calculated.
Regions Incidence 95% CI Prevalence > 50 Y 95%CI
The Capital Region of Denmark 0.17 0.16–0.17 6.28 6.21–6.36
Region of Zealand 0.13 0.13–0.14 4.25 4.16–4.33
Region of Southern Denmark 0.17 0.16–0.17 4.91 4.83–4.98
Region of Central Jutland 0.14 0.13–0.14 5.10 5.02–5.18
The North Denmark Region 0.14 0.13–0.15 3.96 3.86–4.06
Abbreviations: Y = years
doi:10.1371/journal.pone.0132048.t003
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glaucoma in the capital region of Denmark compared to other regions (Fig 2, Table 3). In sup-
port of this regional difference in Denmark, it has previously been shown that the highest num-
ber of glaucoma prevalence was found in Copenhagen followed by the second largest city in
Denmark, Aarhus[9]. Since the higher prevalence of glaucoma was not corresponding to a
higher number of elderly (Table 2), the significant regional differences observed in this study,
may reflect a more readily available healthcare in urban areas. In addition, the population in
rural areas of Denmark may have a tendency to neglect their eye problems, which consequently
leads to an increased number of unrecognized glaucoma cases.
Due to reimbursement from the national healthcare system, all Danish pharmacies have
been obligated to register all prescriptions dispensed to the Danish Registry of Medicinal Prod-
uct Statistics since 1996. In this way an ensured and complete registration, without selection
bias, allows a detailed analysis of distributed glaucoma medication. In comparison, the use of
data based on ICD-10 coding in the National Registry of Patients will underestimate the num-
ber of glaucoma cases due to errors or lack of registration by general ophthalmologists. In the
same matter, surgical procedures and laser treatments for glaucoma will be under-estimated if
using ICD-10 coding. Therefore, an estimation of such procedures will require questionnaire
studies and is beyond the scope of the present study.
Here we investigated the pattern of glaucoma medication in the period from 1996 to 2011
(Fig 3, Table 4). Among the 116,552 identified glaucoma cases the most used mono therapy
changed from β-blockers to prostaglandin analogs in the study period. The change can be
Table 4. Baseline characteristics of glaucomamedication in the Danish population in the period from 1996 to 2011.
Characteristic Total 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 1996 vs. 2011
(p-value)
First choice
β-blockers 22362 2708 2470 1912 1551 1457 1374 1215 1141 1044 1099 1054 978 1040 1084 1131 1124
% 19 38 35 26 22 21 21 18 16 15 16 15 13 13 14 14 13 <0.001
Prostagl. 44337 1466 1891 2523 2441 2387 2514 2795 2886 2780 2933 2893 3023 3249 3108 3411 4041
% 38 20 27 34 34 35 38 41 41 40 44 41 41 42 40 42 47 <0.001
α2-agonists 2774 140 107 211 269 275 229 162 141 154 144 125 142 170 154 171 182
% 2 2 2 3 4 4 3 2 2 2 2 2 2 2 2 2 2 0.5
CAI 22478 1699 1415 1502 1637 1460 1207 1169 1346 1414 941 1246 1590 1525 1537 1567 1230
% 19 24 20 20 23 21 18 17 19 20 14 18 22 20 20 19 14 <0.001
Parasymp. 3423 354 290 265 241 248 217 198 166 154 179 180 174 204 187 186 180
% 3 5 4 4 3 4 3 3 2 2 3 3 2 3 2 2 2 <0.001
Combined 21178 826 813 952 1053 1070 1159 1299 1307 1374 1440 1553 1472 1613 1668 1744 1842
% 18 11 12 13 15 16 17 19 19 20 21 22 20 21 22 21 21 <0.001
Prescription no
1. presc. 80633 4056 3991 4573 4546 4373 4135 4470 4621 4666 4500 4865 5381 5935 6095 6815 7611 .
% 76 66 67 72 72 72 71 73 73 75 74 75 79 81 83 87 91 <0.001
2. presc. 17894 1234 1249 1093 1121 1074 1146 1179 1216 1122 1175 1242 1135 1160 1072 956 720
% 17 20 21 17 18 18 20 19 19 18 19 19 17 16 15 12 9 <0.001
3. presc. 5538 594 506 471 460 430 446 403 380 380 345 330 273 233 163 92 32
% 5 10 8 7 7 7 8 7 6 6 6 5 4 3 2 1 0 <0.001
4. presc. 1442 216 203 153 155 144 114 83 94 78 77 60 36 19 8 2 0
% 1 4 3 2 2 2 2 1 1 1 1 1 1 0 0 0 0 <0.001
5. presc. 282 59 47 45 25 32 24 18 11 11 5 1 3 1 0 0 0
% 0 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 <0.001
Abbreviations: Prostagl. = prostaglandin analogs; Parasymp. = parasympathomimetic drugs; CAI = carbon anhydrase inhibitors; Combined = combination
drugs.
doi:10.1371/journal.pone.0132048.t004
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explained by the introduction of prostaglandin analogs in 1996 as well as a higher pressure-
lowering efficacy of prostaglandin analogs compared to β-blockers[18]. A decrease in the use
of carbon anhydrase inhibitors and parasympathomimetic drugs was found throughout the
studied period, whereas the use of α2-adrenergic agonists remained consistent. Over all, the
use of several simultaneous glaucoma medications decreased throughout the study period
(Table 4). Increased awareness of adherence challenges might explain this decrease. Further-
more, the continuous introduction of combined medications and the introduction of selective
laser treatment and new surgical procedures may also explain the reduced number of patients
receiving multiple glaucoma medications (Table 4). In support of this assumption, the pre-
scription of combination drugs increased significantly throughout the study period (Fig 3,
Table 4). In comparison to the Danish prescription patterns, recent studies investigated the use
of glaucoma medication in the American and the British population, respectively[19,20]. A
similar treatment pattern was found. Both studies found an increased use of prostaglandin ana-
logs along with a decreased use of β-blockers. The only significant difference from the current
study was an increased use of α2-adrenergic agonists among the American population[19].
The lack of increase in α2-adrenergic agonist treatment in Denmark may be due to the unavail-
ability of the α2-adrenergic agonist suspension, Alphagan P, which has been shown to cause
significantly fewer cases of allergy compared to the European suspension[19,21].
Conclusion
To our knowledge the present study is the largest nationwide study ever made and must be a
close-to-real-life-picture of the utilization of glaucoma medication on a nationwide scale. The
age specific incidence rate of glaucoma cases was shown to be constant, and the increased prev-
alence correlates with an aging population. Compared to previous studies the present study
reveals a higher incidence and prevalence than previously estimated. Hence, as many as 3.76%
of citizens above 50 years suffer from glaucoma, and as many as 10% of citizens above 80 years
are treated with glaucoma medication. Increasing evidence implies that systemic diseases
might be associated with glaucoma. Based on the strength of the complete data sample from an
entire population future studies will investigate possible comorbidities with glaucoma, and
hopefully contribute to a better understanding of the management of glaucoma.
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